Gensburger D, Kawashima M, Marotte H, Kanitakis J, Miossec P
Department of Immunology, Hôpital Edouard Hérriot, 69437 Lyon Cedex 03, France.
Ann Rheum Dis. 2005 Jan;64(1):153-5. doi: 10.1136/ard.2003.019323.
Leflunomide is a new oral disease modifying antirheumatic drug with a good safety profile.
The first case of lupus erythematosus in a 58 year old white woman after administration of leflunomide for primary Sjögren's syndrome is reported. The relationship between induced lupus and leflunomide was confirmed by the resolution of the skin rash when the drug was stopped and its recurrence when it was reintroduced following a dose-response effect.
Peripheral blood cells from this patient, from 15 patients with rheumatoid arthritis, and from healthy controls were used in a bioassay, which suggested that leflunomide affected the Th1/Th2 balance. Such a side effect might be related, in part, to the anti-tumour necrosis factor alpha activity of leflunomide.
来氟米特是一种新型口服改善病情抗风湿药物，安全性良好。
报道了一名58岁白人女性在使用来氟米特治疗原发性干燥综合征后发生红斑狼疮的首例病例。停药后皮疹消退，再次用药后皮疹复发且呈剂量反应效应，从而证实了诱发狼疮与来氟米特之间的关系。
该患者、15名类风湿关节炎患者及健康对照者的外周血细胞用于生物测定，结果提示来氟米特影响Th1/Th2平衡。这种副作用可能部分与来氟米特的抗肿瘤坏死因子α活性有关。
